A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study
to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of
IgA nephropathy.